Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.
about
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis.Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Alemtuzumab in the long-term t ...... and data from the real world.
@en
Alemtuzumab in the long-term t ...... and data from the real world.
@nl
type
label
Alemtuzumab in the long-term t ...... and data from the real world.
@en
Alemtuzumab in the long-term t ...... and data from the real world.
@nl
prefLabel
Alemtuzumab in the long-term t ...... and data from the real world.
@en
Alemtuzumab in the long-term t ...... and data from the real world.
@nl
P2860
P356
P1476
Alemtuzumab in the long-term t ...... and data from the real world.
@en
P2093
Katja Thomas
P2860
P304
P356
10.1177/1756285617722706
P577
2017-08-04T00:00:00Z